Ascendiant Capital Markets Trims PAVmed (NASDAQ:PAVM) Target Price to $21.00

PAVmed (NASDAQ:PAVM) had its price target lowered by Ascendiant Capital Markets from $22.00 to $21.00 in a research report sent to investors on Tuesday, Marketbeat reports. Ascendiant Capital Markets currently has a buy rating on the stock.

Separately, Lake Street Capital upgraded shares of PAVmed to a strong-buy rating in a report on Wednesday, May 15th.

PAVmed Price Performance

Shares of NASDAQ:PAVM opened at $1.72 on Tuesday. PAVmed has a 12 month low of $0.60 and a 12 month high of $6.27. The firm has a market capitalization of $16.22 million, a price-to-earnings ratio of -0.19 and a beta of 0.66. The business’s 50 day simple moving average is $0.93 and its 200-day simple moving average is $1.50.

PAVmed (NASDAQ:PAVM) last posted its earnings results on Tuesday, August 13th. The company reported ($0.84) earnings per share for the quarter. The business had revenue of $0.98 million during the quarter. On average, equities analysts anticipate that PAVmed will post -5.88 earnings per share for the current year.

PAVmed Company Profile

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.